#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Ornithine transcarbamoylase deficiency Malignant peritoneal neoplasm Thalassaemia beta Liver transplant rejection Factor VIII deficiency Ventricular tachycardia Acromegaly Progressive multifocal leukoencephalopathy Gastrointestinal disorder Emphysema Anti-glomerular basement membrane disease B-cell small lymphocytic lymphoma recurrent Bronchopulmonary aspergillosis Aicardi-Goutieres syndrome Cholestatic pruritus More trials…

    Learn about Rare Diseases

    Methylmalonic acidaemia – Diagnostics Marginal zone lymphoma Waldenstrom’s macroglobulinaemia Pulmonary fibrosis – Life with Disease Glycogen storage disease type II – Diagnostics Hyperoxaluria – Diagnostics Erdheim-Chester disease – Treatment Hyperoxaluria Pleomorphic leiomyosarcoma Myelodysplastic syndrome with excess blasts More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Verapamil Miglustat GSKVX000000025896 AGA2118 Dirocaftor IMB 101 Human Coagulation Factor Ix Fluciclovine (18F) Dersimelagon Phosphate Fenoterol Hydrobromide Clarithromycin Gefitinib Dextran 70 Pc14586 Warfarin LTG-001 Lisinopril ALE1 Deferoxamine Neostigmine Methylsulfate More therapies…

    Learn about Your Condition

    Epiphysiolysis Status epilepticus Pigmentary glaucoma Plasma cell myeloma Peritoneal dialysis Peripheral artery stenosis Oropharyngeal cancer Sepsis Biliary tract operation Follicular lymphoma stage III Hydrocephalus Dysmenorrhoea Transitional cell carcinoma Schizophreniform disorder Mucopolysaccharidosis I More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Squamous cell carcinoma of head and neck

  • Study Comparing Radiotherapy Alone to Radiotherapy with Cisplatin for Patients with Sinus or Salivary Gland Tumors

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Cisplatin
    Belgium France

  • Study Comparing Avelumab, Cetuximab, and Radiotherapy with Standard Treatments for Patients with Advanced Head and Neck Squamous Cell Carcinoma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Avelumab
    • Cetuximab
    • Cisplatin
    France

  • Study on the Effects of IO102 Hydrochloride and IO103 Acetate for Patients with Head and Neck Cancer

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Io102 Hydrochloride
    • Io103 Acetate
    Belgium

  • Study on Atezolizumab and Tiragolumab for Patients with Head and Neck Cancer, Metastatic Melanoma, and Other Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    • Neoplasm malignant
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Atezolizumab
    • Tiragolumab
    The Netherlands

  • Study Comparing Weekly Low Dose Cisplatin to High Dose Every Three Weeks for Sarcopenic Patients with Head and Neck Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Cisplatin
    The Netherlands

  • Study of TransCon TLR7/8 Agonist, TransCon IL-2 β/γ, and Pembrolizumab for Patients with Advanced Head and Neck Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Acp-017
    • Transcon Il-2Β/Γ
    • Pembrolizumab
    Germany Hungary Italy Poland Spain
Previous Page
1 … 6 7 8 9 10 … 12
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!